Recent News

• 05.28.2026 - Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
• 04.29.2026 - Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
• 04.16.2026 - Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
• 04.14.2026 - Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
• 04.13.2026 - Biomerica Reports Third Quarter Fiscal 2026 Financial Results
• 03.18.2026 - Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
• 03.05.2026 - Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
• 02.26.2026 - Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
• 02.18.2026 - Vietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution
• 01.14.2026 - Biomerica Reports Second Quarter Fiscal 2026 Financial Results

Recent Filings

• 04.13.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 02.27.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 01.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities